ArticlePLoS neglected tropical diseases2022
Antibiotic persistence of intracellular Brucella abortus.
Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Determinants of relapse and delayed convalescence in patients with Brucellosis: a one-year prospective follow-up.Irish journal of medical science · 2026Article
- CueO Possesses Copper Detoxification Activity Linking Bacterial Virulence and Drug Resistance in Brucella.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Pediatric brucellosis: predictors of hospitalization, complications, and relapse in a nationwide multicenter cohort.European journal of pediatrics · 2026Article
- Molecular Interplay of Brucellosis and Tuberculosis: Insights into Telomere Biology, Oxidative Stress, and Drug Resistance Mechanisms.Diseases (Basel, Switzerland) · 2026Review
- An integrated subtractive genomics and immunoinformatics approach for designing a universal multi-epitope vaccine againstFrontiers in bioinformatics · 2026Article
- Development and evaluation of novel Brucella diagnostic antigen protein ST.BMC infectious diseases · 2025Article
- Seroprevalence and Associated Risk Factors of Human Brucellosis in a Farming and Animal Health Community in South Africa, 2015-2016.Tropical medicine and infectious disease · 2025Article
- Monitoring intracellular replication dynamics unveils high proportion of non-replicating antibiotic-tolerant Staphylococcus aureus inside osteoblasts.PLoS pathogens · 2025Article
- Reactivation of hidden-latentAntimicrobial agents and chemotherapy · 2025Article
- Spatiotemporal dynamics of Brucella immune evasion across infection stages.Frontiers in immunology · 2025Review
- A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein againstClinical and experimental vaccine research · 2025Article
- A case of polycystic kidney disease infection caused byFrontiers in medicine · 2025Article
- The putative type 4 secretion system effector BspD is involved in maintaining envelope integrity of the pathogenmSphere · 2024Article
- Brucellosis: Unveiling the complexities of a pervasive zoonotic disease and its global impacts.Open veterinary journal · 2024Review
- Intoxication of antibiotic persisters by host RNS inactivates their efflux machinery during infection.PLoS pathogens · 2024Article
- The (p)ppGpp synthetase Rsh promotes rifampicin tolerant persister cell formation inFrontiers in microbiology · 2024Article
- Lipopolysaccharides ofToxins · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman brucellosis caused by the facultative intracellular pathogen Brucella spp. is an endemic bacterial zoonosis manifesting as acute or chronic infections with high morbidity. Treatment typically involves a combination therapy of two antibiotics for several weeks to months, but despite this harsh treatment relapses occur at a rate of 5-15%. Although poor compliance and reinfection may account for a fraction of the observed relapse cases, it is apparent that the properties of the infectious agent itself may play a decisive role in this phenomenon. METHODOLOGY/PRINCIPAL
findingsWe used B. abortus carrying a dual reporter in a macrophage infection model to gain a better understanding of the efficacy of recommended therapies in cellulo. For this we used automated fluorescent microscopy as a prime read-out and developed specific CellProfiler pipelines to score infected macrophages at the population and the single cell level. Combining microscopy of constitutive and induced reporters with classical CFU determination, we quantified the protective nature of the Brucella intracellular lifestyle to various antibiotics and the ability of B. abortus to persist in cellulo despite harsh antibiotic treatments. CONCLUSION/SIGNIFICANCE: We demonstrate that treatment of infected macrophages with antibiotics at recommended concentrations fails to fully prevent growth and persistence of B. abortus in cellulo, which may be explained by a protective nature of the intracellular niche(s). Moreover, we show the presence of bona fide intracellular persisters upon antibiotic treatment, which are metabolically active and retain the full infectious potential, therefore constituting a plausible reservoir for reinfection and relapse. In conclusion, our results highlight the need to extend the spectrum of models to test new antimicrobial therapies for brucellosis to better reflect the in vivo infection environment, and to develop therapeutic approaches targeting the persister subpopulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.